MAPK8IP3 and non-small cell lung carcinoma: Our work illuminated a novel mechanism of osimertinib resistance in NSCLC, and implied that M2 type TAM-derived exosomal MSTRG.292666.16/ miR-6836-5p/ MAPK8IP3 serves as a novel therapeutic target and may have potential therapeutic value in treating osimertinib resistance in NSCLC.